TY - JOUR
T1 - Persistent Brain Connectivity Changes in Healthy Volunteers Following Nitrous Oxide Inhalation
AU - Palanca, Ben Julian A.
AU - Conway, Charles R.
AU - Zeffiro, Thomas
AU - Gott, Britt M.
AU - Nguyen, Thomas
AU - Janski, Alvin
AU - Jain, Nisha
AU - Komen, Helga
AU - Burke, Broc A.
AU - Zorumski, Charles F.
AU - Nagele, Peter
N1 - Funding Information:
CRC receives research funding through Washington University from LivaNova, PLC and is the Lead Investigator of the RECOVER trial. He has also received consultation fees from Sage Therapeutics. Sage and LivaNova were not involved in this work. CFZ serves on the Scientific Advisory Board of Sage Therapeutics and has equity in the company. PN is currently receiving funding from the National Institute of Mental Health, the American Foundation for Prevention of Suicide, and the Brain Behavior Foundation; PN has received research funding and honoraria from Roche Diagnostics and Abbott Diagnostics and has previously filed for intellectual property protection related to the use of nitrous oxide in major depression (“Compositions and methods for treating depressive disorders”; US20170071975A1). All other authors report no biomedical financial interests or potential conflicts of interest.
Funding Information:
This work was supported by National Institute of Mental Health (Grant No. R21MH108901 [to CRC and PN] and Grant No. P50MH122379 [to CFZ]), Taylor Family Institute for Innovative Psychiatry Research (to CRC and CFZ, Grant No. 1U01MH128483 [to BJAP]), Washington University Center for Perioperative Mental Health (Grant No. P50 MH122351 [to BJAP]), and University of Chicago (to PN). Additionally, this work was supported by funds provided by the McDonnell Center for Systems Neuroscience at Washington University in St. Louis (to CRC and PN). PN, CRC, and CFZ obtained funding. BJAP had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. PN, CRC, and CFZ were responsible for study concept and design. All authors were responsible for acquisition, analysis, and interpretation of data. BJAP, CRC, TZ, CFZ, and PN drafted the original manuscript. TZ performed statistical analyses. All authors critically revised the manuscript for important intellectual content. We appreciate the efforts of Frank Brown, Jacob Bolzenius, and Linda Barnes in assisting with the execution of the study. We thank the following colleagues for administering our inhalation sessions: Branden Yee, Michael Montana, Andreas Kokoefer, Jaime Brown-Shpigel, Christian Guay, Tracy Lanes, Sara Pitchford, and Marlette Williams. Preliminary presentation of these data occurred at the 2022 American Society of Anesthesiologists Meeting. CRC receives research funding through Washington University from LivaNova, PLC and is the Lead Investigator of the RECOVER trial. He has also received consultation fees from Sage Therapeutics. Sage and LivaNova were not involved in this work. CFZ serves on the Scientific Advisory Board of Sage Therapeutics and has equity in the company. PN is currently receiving funding from the National Institute of Mental Health, the American Foundation for Prevention of Suicide, and the Brain Behavior Foundation; PN has received research funding and honoraria from Roche Diagnostics and Abbott Diagnostics and has previously filed for intellectual property protection related to the use of nitrous oxide in major depression (“Compositions and methods for treating depressive disorders”; US20170071975A1). All other authors report no biomedical financial interests or potential conflicts of interest. ClinicalTrials.gov: NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits; https://clinicaltrials.gov/ct2/show/NCT02994433; NCT02994433.
Funding Information:
This work was supported by National Institute of Mental Health (Grant No. R21MH108901 [to CRC and PN] and Grant No. P50MH122379 [to CFZ]), Taylor Family Institute for Innovative Psychiatry Research (to CRC and CFZ, Grant No. 1U01MH12848 3 [to BJAP]), Washington University Center for Perioperative Mental Health (Grant No. P50 MH122351 [to BJAP]), and University of Chicago (to PN). Additionally, this work was supported by funds provided by the McDonnell Center for Systems Neuroscience at Washington University in St. Louis (to CRC and PN).
Publisher Copyright:
© 2023 The Authors
PY - 2023
Y1 - 2023
N2 - Background: Nitrous oxide holds promise in the treatment of major depressive disorder. Its psychotropic effects and NMDA receptor antagonism have led to comparisons with ketamine. Despite longstanding use, persistent effects of nitrous oxide on the brain have not been characterized. Methods: Sixteen healthy volunteers were recruited in a double-blind crossover study. In randomized order, individuals underwent a 1-hour inhalation of either 50% nitrous oxide/oxygen or air/oxygen mixtures. At least two 7.5-minute echo-planar resting-state functional magnetic resonance imaging scans were obtained before and at 2 and 24 hours after each inhalation (average 130 min/participant). Using the time series of preprocessed, motion artifact–scrubbed, and nuisance covariate–regressed imaging data, interregional signal correlations were measured and converted to T scores. Hierarchical clustering and linear mixed-effects models were employed. Results: Nitrous oxide inhalation produced changes in global brain connectivity that persisted in the occipital cortex at 2 and 24 hours postinhalation (p < .05, false discovery rate–corrected). Analysis of resting-state networks demonstrated robust strengthening of connectivity between regions of the visual network and those of the dorsal attention network, across 2 and 24 hours after inhalation (p < .05, false discovery rate–corrected). Weaker changes in connectivity were found between the visual cortex and regions of the frontoparietal and default mode networks. Parallel analyses following air/oxygen inhalation yielded no significant changes in functional connectivity. Conclusions: Nitrous oxide inhalation in healthy volunteers revealed persistent increases in global connectivity between regions of primary visual cortex and dorsal attention network. These findings suggest that nitrous oxide inhalation induces neurophysiological cortical changes that persist for at least 24 hours.
AB - Background: Nitrous oxide holds promise in the treatment of major depressive disorder. Its psychotropic effects and NMDA receptor antagonism have led to comparisons with ketamine. Despite longstanding use, persistent effects of nitrous oxide on the brain have not been characterized. Methods: Sixteen healthy volunteers were recruited in a double-blind crossover study. In randomized order, individuals underwent a 1-hour inhalation of either 50% nitrous oxide/oxygen or air/oxygen mixtures. At least two 7.5-minute echo-planar resting-state functional magnetic resonance imaging scans were obtained before and at 2 and 24 hours after each inhalation (average 130 min/participant). Using the time series of preprocessed, motion artifact–scrubbed, and nuisance covariate–regressed imaging data, interregional signal correlations were measured and converted to T scores. Hierarchical clustering and linear mixed-effects models were employed. Results: Nitrous oxide inhalation produced changes in global brain connectivity that persisted in the occipital cortex at 2 and 24 hours postinhalation (p < .05, false discovery rate–corrected). Analysis of resting-state networks demonstrated robust strengthening of connectivity between regions of the visual network and those of the dorsal attention network, across 2 and 24 hours after inhalation (p < .05, false discovery rate–corrected). Weaker changes in connectivity were found between the visual cortex and regions of the frontoparietal and default mode networks. Parallel analyses following air/oxygen inhalation yielded no significant changes in functional connectivity. Conclusions: Nitrous oxide inhalation in healthy volunteers revealed persistent increases in global connectivity between regions of primary visual cortex and dorsal attention network. These findings suggest that nitrous oxide inhalation induces neurophysiological cortical changes that persist for at least 24 hours.
KW - Depression
KW - Functional connectivity
KW - Functional magnetic resonance imaging
KW - Ketamine
KW - NMDA receptor
KW - Nitrous oxide
UR - http://www.scopus.com/inward/record.url?scp=85151399848&partnerID=8YFLogxK
U2 - 10.1016/j.bpsgos.2023.01.006
DO - 10.1016/j.bpsgos.2023.01.006
M3 - Article
AN - SCOPUS:85151399848
SN - 2667-1743
JO - Biological Psychiatry Global Open Science
JF - Biological Psychiatry Global Open Science
ER -